In a study of 7,422 nursing home residents with type 2 diabetes, 17% met criteria for glycemic overtreatment and another 23% met criteria for potential overtreatment. (Journal of the American Geriatrics Society)
Aeterna Zentaris announced some delays in patient recruitment for its ongoing pivotal phase III DETECT efficacy and safety study of 1 mg/kg macimorelin acetate (AEZS-130-P02) as a growth hormone stimulation test in pediatric patients with suspected growth hormone deficiency.
A Welsh couple were charged with the death of their 16-year-old daughter after they allegedly allowed her to progress to morbid obesity and failed to get medical treatment for her. (The Guardian)
An Australian study of 193 young adults who were conceived through assisted reproductive technology found they had better quality of life, particularly with social relationships and environment domains, versus those who were conceived naturally. (Human Fertility)
Fermented okara: the next frontier in tackling obesity? (ScienceDaily)
Allergan and Apollo Endosurgery beat a False Claims Act lawsuit in a Maryland court after a whistleblower alleged that the companies would exchange purchases of its Lap Band device for free advertising of surgeons. (Bloomberg Law)
One year of treatment with the blood pressure drug verapamil (Verelan) was linked with better insulin production by beta cells in people with type 1 diabetes, reducing the amount of insulin required. (Nature Communications)
The FDA cleared Amolyt Pharma's investigational new drug application for the ongoing clinical proof-of-concept trial of AZP-3601, an investigational therapeutic peptide, in patients with hypoparathyroidism, with top-line data expected in mid-2022.
Rani Therapeutics announced it initiated a phase I study of RT-102 -- an oral version of the human parathyroid hormone analog PTH(1-34) -- for the treatment of osteoporosis.
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)